Drug Trial Radar · NCT06218030
Adjunctive Treatment With L-methylfolate for Treatment-Resistant Generalized Anxiety Disorder: a Pilot Study
Last checked: Nov 20, 2026Latest source record: May 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
10
Planned (sponsor's estimate)
Start
Oct 22, 2024
Primary completion
Apr 1, 2026
Study completion May 1, 2026
Sponsor
- Lead sponsor
- Queen's UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 23, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this feasibility study is to determine the tolerability and safety of add on treatment with L-methylfolate in patients with treatment-resistant generalized anxiety disorder (GAD). The primary objective is to monitor for side effects and other risks associated with the treatment. Secondary objectives are to compare the severity of symptoms, serum levels of folate, vitamin B12, C-reactive protein, homocysteine, tumor necrosis factor alpha and interleukin 6 before and after treatment. Participants will continue with their usual treatment for GAD and receive add on treatment with L-methylfolate 15 mg per day for 8 weeks. All participants will receive the same intervention.
Conditions
- Generalized Anxiety Disorder
Interventions
L-methylfolateDrug
Oral administration of L-methylfolate 15 mg per day for 8 weeks. The study drug will be given in addition to the standard of care (SOC) for GAD.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse eventsTime frame: Throughout the study, 8 weeks
- Incidence of treatment-emergent side effects measured with the ASECTime frame: Baseline visit, 4-week visit and 8-week visit.
- Response to treatment defined by CGI-I score below 3Time frame: 4-week visit and 8-week visit.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Kingston Health Sciences Centre
Kingston, Ontario, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.